All In Biotech

Company

Pharmaand

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

2

2 still marketed

Novel approvals

2

Approvals since 2021

5

Originals and new uses

Phase 3 trials

5

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Rubraca new use Dec 17, 2025
  • Rubraca new use Dec 17, 2025
  • Pegasys new use Dec 11, 2023
  • Rubraca new use Priority reviewDec 21, 2022
  • Rubraca new use Priority reviewJun 10, 2022
  • Rubraca new use Priority reviewOct 8, 2020
  • Rubraca new use Breakthrough therapyPriority reviewMay 15, 2020
  • Rubraca new use Priority reviewOrphanApr 6, 2018
  • Pegasys new use Oct 13, 2017
  • Rubraca approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDec 19, 2016

Drugs in development (0)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

No investigational drugs in Phase 2 or 3 trials under this sponsor name.

Recruiting Phase 3 trials

Largest first.

No recruiting Phase 3 trials under this sponsor name.

Marketed drugs (2)

Newest FDA action first.

  • Rubraca Rucaparib Camsylate · 2016
  • Pegasys Peginterferon Alfa-2a · 2002

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.